Premium
The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology
Author(s) -
Pinsky Paul F.,
Church Timothy R.,
Izmirlian Grant,
Kramer Barnett S.
Publication year - 2013
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28326
Subject(s) - medicine , lung cancer , national lung screening trial , adenocarcinoma , lung cancer screening , poisson regression , cancer , relative risk , lung , oncology , confidence interval , population , environmental health
BACKGROUND The National Lung Screening Trial (NLST), which compared lung cancer screening with low‐dose computed tomography (LDCT) versus chest radiography (CXR), demonstrated a statistically significant mortality benefit of LDCT screening. In the current study, the authors performed a post hoc analysis to examine whether the benefit was affected by various baseline factors, including age, sex, and smoking status, and whether it differed by tumor histology. METHODS Lung cancer death rates were computed as events over person‐years of observation; the mortality risk ratio (RR) was defined as the lung cancer death rate in the LDCT versus CXR trial arms. Poisson regression was used to test for interactions of sex, age (< 65 years vs ≥ 65 years), and smoking status (current vs former) with trial arm. Mortality RRs were also computed for specific lung cancer histologies. RESULTS The overall mortality RR was 0.92 in men and 0.73 in women, with a P value for interaction of .08. RRs were similar for individuals aged < 65 years versus those aged ≥ 65 years (0.82 vs 0.87), and for current versus former smokers (0.81 vs 0.91). By tumor histology, mortality RRs were 0.75 for adenocarcinoma, 0.71 for all non‐small cell lung cancers except squamous, 1.23 for squamous cell carcinoma, and 0.90 for small cell carcinoma. RRs were similar for men and women for nonsquamous non‐small cell lung cancers (0.71 and 0.70, respectively); women were found to have lower RRs for small cell and squamous cell carcinoma. CONCLUSIONS A benefit of LDCT did not appear to vary substantially by age or smoking status; there was weak evidence of a differential benefit by sex. A differential benefit across lung cancer histologies may exist. Cancer 2013 ;119:3976–3983. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.